ASCO26: Blood cancer readouts take centre stage - Pharmaceutical Technology

Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference. Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference. Pharmaceutical Technology covers some of the highlights in blood cancer from ASCO 2026. Credit: inspiring.team / Shutterstock.com. With the 2026 American Society of Clinical Oncology (ASCO) conference wrapping up, many are turning their attention to key readouts in the blood cancer space, with focus darting from more common indications like chronic lymphocytic leukaemia (CLL) and multiple myeloma to rare conditions like myelofibrosis.…

Source: Pharmaceutical Technology